aColumbia University Department of Epidemiology, New York, NY
bDepartment of Population Health, NYU Grossman School of Medicine, New York, NY
cDepartment of Biostatistics, Columbia University, New York, NY
dRutgers University, Center for Health Services Research, Institute for Health, and School of Social Work, New Brunswick, NJ
eNetwork for Public Health Law, Edina, MN
fColumbia University Department of Psychiatry, New York, NY.
Submitted September 1, 2020; accepted July 15, 2021
The results reported herein correspond to specific aims of grant R01DA048572 to investigators Cerda and Martins from the National Institute on Drug Abuse. This work was also partially supported by grants 1R01DA047347, 1R01DA048860, and K01DA049950 from the National Institute on Drug Abuse, R18 HS023258 from the Agency for Healthcare Quality and Research, UL1TR003017 from the National Center for Advancing Translational Sciences, and the New Jersey Health Foundation.
K.M.K. reports personal fees related to consultation in opioid product litigation. All other authors report no conflict of interest.
Code for replicating our analyses can be found at: https://github.com/phios-CUEpidemiology/OpioidML
Supplemental digital content is available through direct URL citations in the HTML and PDF versions of this article (www.epidem.com).
Correspondence: Silvia S. Martins, Department of Epidemiology, Columbia University Mailman School of Public Health, 722 West 168th St, Room 509, New York, NY 10032. E-mail: [email protected].
